PetVivo Holdings, Inc. PETV
0.59 USD -0.03 (-4.84%)
At closeNov 3, 2026, 4:00 PM EST
0.56 Day range 0.605
0.56 52-week range 1.44
- YTD
- -48.25%
- 1 year
- -59.59%
- Market cap
- 22.39M
- Revenue (ttm)
- 1.05M
- EPS (ttm)
- -0.32
- Shares out
- 16.77M
- Forward P/E
- -0.96
- YTD return
- -48.25%
- 1-year return
- -59.59%
- Volume
- 18.09K
- Avg volume
- 11.37K
- Open
- 0.605
- Previous close
- 0.62
- Day's range
- 0.56 – 0.605
- 52-week range
- 0.56 – 1.44
- Beta
- 2.10
- Analysts
- Buy
2Y +0.0900 (+18.00%)
Key statistics
- Enterprise value
- 14.82M
- PEG ratio
- 0.00
- Price / sales
- 11.54
- Price / book
- 12.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 16.80%
- Free cash flow
- -4.02M
- Total cash
- 80.08K
- Total debt
- 1.40M
- Return on equity
- -1266.46%
- Short % of float
- 1.00%
- 50-day average
- 0.92812
- 200-day average
- 1.35
Analyst view
Consensus: buy
Buy
Price target (mean) —
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PETV Revenue — quarterly 595.89K
PETV Net income — quarterly -1.75M
PETV EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.11 | — | — |
| Jun 28, 2024 | Mar 1, 2024 | 0.00 | -0.14 | — | — |
| Feb 12, 2024 | Dec 1, 2023 | 0.00 | -0.12 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.23 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.25 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 11, 2021 | ThinkEquity | init | — | Buy |
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- petvivo.com
News
PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES 
Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors 
Michael Handley Joins PetVivo Holdings, Inc. Board of Directors 
PETVIVO ANIMAL HEALTH, INC. RELEASES CONFERENCE AND EXHIBIT SCHEDULE FOR 2026-2027 
PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION 
PetVivo Holdings, Inc. (PETV) Q1 2027 Earnings Call Transcript 
PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027 
PetVivo Sets Fiscal First Quarter 2027 Conference Call for Friday, August 14, 2026 at 5:00 p.m. ET 
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM 
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
Your note
Sign in to keep a note on PETV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASH GREGORY D | Director | Conversion of Exercise of derivative security | Jun 29, 2022 | 59,267 |
| COSTANTINO ROBERT J | Director | Purchase | Mar 14, 2023 | 9,703 |
| DEMING DAVID DON | Director | Stock Award(Grant) | Sep 30, 2021 | 29,890 |
| DOLAN JOHN FITZGERALD | Officer and Director | Stock Award(Grant) | Sep 8, 2021 | 541,239 |
| JASPER JOSEPH WILLIAM | Director | Purchase | Mar 12, 2023 | 0 |
| JOHNSON SCOTT MITCHELL | Director | Stock Award(Grant) | Sep 30, 2021 | 169,726 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bard Associates Inc. | 6.15% | 436,500 | 859.90K | Jun 29, 2023 |
| Vanguard Group Inc | 3.29% | 233,055 | 459.12K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.66% | 47,045 | 92.68K | Jun 29, 2023 |
| State Street Corporation | 0.65% | 46,229 | 91.07K | Jun 29, 2023 |
| Regal Investment Advisors, LLC | 0.30% | 21,377 | 42.11K | Jun 29, 2023 |
| Asset Dedication, Llc | 0.21% | 14,569 | 28.70K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.44% | 173,200 | 341.20K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.84% | 59,855 | 117.91K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.39% | 27,820 | 57.87K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.17% | 12,298 | 25.58K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.05% | 3,291 | 6.84K | May 30, 2023 |